Physician profile
Matthew E Modansky
NPI 1619048386
$1,205.05
in general payments reported to CMS, 2019-2025
19 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.22 · 2020: $26.52 · 2021: $22.27 · 2022: $67.92 · 2023: $72.88 · 2024: $537 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $272.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $151.19 | 2020-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $124.53 | 2019-2025 | Farxiga, Tezspire, Airsupra |
| Amgen INC. | $113.90 | 2022-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $103.75 | 2023-2025 | Veozah |
| Pfizer INC. | $83.37 | 2024-2025 | |
| Glaxosmithkline, LLC. | $81.22 | 2024-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $63.10 | 2019-2024 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.26 | 2025 | |
| Sanofi-Aventis U.S. LLC | $24.45 | 2024 | |
| Abbott Laboratories | $22.27 | 2021 | |
| Hologic Sales and Service, LLC | $21.64 | 2023 | Aptima, Thinprep 2000 Processor |
| Boston Scientific Corporation | $21.30 | 2025 | General - Pain Management |
| Abbvie INC. | $19.68 | 2024 | |
| Sanofi Pasteur INC. | $17.51 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $16.54 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $14.75 | 2022 | |
| Amarin Pharma, INC. | $14.37 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Modansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.